Loading clinical trials...
Loading clinical trials...
An Open Label Multicenter Phase Ib/II Trial to Determine the Dose of BI 836826 in Combination With Gemcitabine and Oxaliplatin (GemOx) and the Efficacy of BI 836826-GemOx Versus Rituximab (R)- GemOx (R-GemOx) in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma (DLBCL) Who Are Not Eligible for, or Have Relapsed/Progressed After Autologous/Allogeneic Stem Cell Transplant
Conditions
Interventions
BI 836826
GemOx
+2 more
Locations
7
Belgium
Jessa Ziekenhuis - Campus Virga Jesse
Hasselt, Belgium
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Istituto Clinico Humanitas
Rozzano (MI), Italy
A. O. S. Maria della Misericordia
Udine, Italy
Hospital Germans Trias i Pujol
Badalona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Start Date
January 28, 2016
Primary Completion Date
March 16, 2018
Completion Date
March 16, 2018
Last Updated
June 17, 2019
NCT06528301
NCT03293173
NCT02278796
NCT03744676
NCT05327725
NCT02031419
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions